JP2019516768A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516768A5 JP2019516768A5 JP2018561725A JP2018561725A JP2019516768A5 JP 2019516768 A5 JP2019516768 A5 JP 2019516768A5 JP 2018561725 A JP2018561725 A JP 2018561725A JP 2018561725 A JP2018561725 A JP 2018561725A JP 2019516768 A5 JP2019516768 A5 JP 2019516768A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- immune checkpoint
- ctl
- cancer
- apc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662341402P | 2016-05-25 | 2016-05-25 | |
| US62/341,402 | 2016-05-25 | ||
| PCT/IB2017/000740 WO2017203362A1 (en) | 2016-05-25 | 2017-05-25 | Immune checkpoint inhibitors and cytotoxic t cells for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019516768A JP2019516768A (ja) | 2019-06-20 |
| JP2019516768A5 true JP2019516768A5 (https=) | 2020-07-02 |
Family
ID=60411124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018561725A Withdrawn JP2019516768A (ja) | 2016-05-25 | 2017-05-25 | がんの治療のための免疫チェックポイント阻害剤及び細胞傷害性ｔ細胞 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3463398A4 (https=) |
| JP (1) | JP2019516768A (https=) |
| KR (1) | KR20190028664A (https=) |
| CN (1) | CN109496155A (https=) |
| AR (1) | AR108624A1 (https=) |
| AU (1) | AU2017271128A1 (https=) |
| CA (1) | CA3023845A1 (https=) |
| SG (1) | SG11201809541UA (https=) |
| WO (1) | WO2017203362A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11918634B2 (en) * | 2017-08-10 | 2024-03-05 | Good T Cells, Inc. | Method for activating T cells for cancer treatment |
| WO2020227279A1 (en) * | 2019-05-06 | 2020-11-12 | Hasumi International Research Foundation | Therapy and methods of introducing immature dendritic cells and/or cytotoxic t lymphocyte and anti pd-1 / pd-l1 antibody for treatment of tumors |
| CN110452870A (zh) * | 2019-05-20 | 2019-11-15 | 河南省肿瘤医院 | 一种肿瘤特异性t细胞的分离培养方法及由其获得的产品 |
| BR112022000790A2 (pt) * | 2019-07-15 | 2022-04-12 | Neogene Therapeutics B V | Método para isolar genes tcr |
| AU2020371562A1 (en) * | 2019-10-23 | 2022-06-09 | The Council Of The Queensland Institute Of Medical Research | Adoptive immunotherapy |
| AU2021285044A1 (en) * | 2020-06-03 | 2022-12-08 | Institute For Research In Biomedicine | Combination of an ATP-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7794710B2 (en) * | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
| KR101523391B1 (ko) * | 2006-12-27 | 2015-05-27 | 에모리 유니버시티 | 감염 및 종양 치료를 위한 조성물 및 방법 |
| WO2010065959A1 (en) * | 2008-12-05 | 2010-06-10 | Northeastern University | Method of preparing adenosine-resistant anti-tumor t lymphocytes for adoptive immunotherapy |
| KR101749195B1 (ko) * | 2011-12-12 | 2017-06-20 | 셀 메디카 리미티드 | T 세포들을 증식시키는 방법 |
| US9381244B2 (en) * | 2012-09-07 | 2016-07-05 | King's College London | VISTA modulators for diagnosis and treatment of cancer |
| IL292510A (en) * | 2013-11-05 | 2022-06-01 | Cognate Bioservices Inc | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
| WO2015157636A1 (en) * | 2014-04-10 | 2015-10-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy |
| CA3017170C (en) * | 2014-09-17 | 2021-03-23 | The Johns Hopkins University | Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells |
| KR20170074235A (ko) * | 2014-10-31 | 2017-06-29 | 메사추세츠 인스티튜트 오브 테크놀로지 | 면역 세포로의 생체분자의 전달 |
-
2017
- 2017-05-25 JP JP2018561725A patent/JP2019516768A/ja not_active Withdrawn
- 2017-05-25 KR KR1020187037498A patent/KR20190028664A/ko not_active Withdrawn
- 2017-05-25 CN CN201780045909.0A patent/CN109496155A/zh active Pending
- 2017-05-25 CA CA3023845A patent/CA3023845A1/en not_active Abandoned
- 2017-05-25 WO PCT/IB2017/000740 patent/WO2017203362A1/en not_active Ceased
- 2017-05-25 AU AU2017271128A patent/AU2017271128A1/en not_active Abandoned
- 2017-05-25 EP EP17802270.3A patent/EP3463398A4/en not_active Withdrawn
- 2017-05-25 SG SG11201809541UA patent/SG11201809541UA/en unknown
- 2017-05-26 AR ARP170101457A patent/AR108624A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019516768A5 (https=) | ||
| Li et al. | Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma | |
| ES2894257T3 (es) | Epítopos restringidos por MHC-E, moléculas de unión y métodos y usos relacionados | |
| JP7705911B2 (ja) | Ｈｉｖワクチン並びにその作製方法及び使用方法 | |
| JP7693813B2 (ja) | Ｈｉｖワクチン及び使用方法 | |
| US20250312428A1 (en) | Heterologous Prime Boost Vaccine | |
| WO2021247534A2 (en) | Compositions and methods for treating merkel cell carcinoma (mcc) using hla class i specific epitopes | |
| Liu et al. | Soluble PD-1-based vaccine targeting MUC1 VNTR and survivin improves anti-tumor effect | |
| JP2019520332A5 (https=) | ||
| Tenesaca et al. | Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors | |
| AR108624A1 (es) | Combinaciones terapéuticas para el tratamiento del cáncer | |
| Wang et al. | Generalization of neoantigen-based tumor vaccine by delivering peptide-MHC complex via oncolytic virus | |
| Seah et al. | Influenza-induced, helper-independent CD8+ T cell responses use CD40 costimulation at the late phase of the primary response | |
| JP2024514707A (ja) | 免疫療法における使用のための組成物及び方法 | |
| TWI921443B (zh) | Ｈｉｖ疫苗及使用方法 | |
| US20240424090A1 (en) | Compositions and methods for use in immunotherapy | |
| Lim et al. | Relationship between Osteosarcoma Therapy and Tumorigenesis, Metastasis, Immune Evasion, and Chemoresistance | |
| Neerincx et al. | Antibody-mediated delivery of TAPBPR enables the redirection of virus-specific T cell responses to tumour cells | |
| Dlamini et al. | Current immunotherapeutic treatments in colon cancer | |
| Hagel | Systematic interrogation of tumor cell resistance to CAR T cell therapy in pancreatic cancer | |
| Tenesaca-Cayambe et al. | Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors | |
| HK40095916A (zh) | Hiv疫苗及其使用方法 |